{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T11:30:16Z","timestamp":1794396616516,"version":"4.9.0"},"reference-count":42,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"unspecified","delay-in-days":84,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2025,7,28]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>In the UK, pharmacological management of patients with heart failure (HF) occurs predominantly in general practice. Using data from the Clinical Practice Research Datalink, we examined the prevalence and risk factors for medication non-adherence and its association with hospitalisation and mortality over a 9-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study of 127 927 patients, \u226518 years old in England with incident HF diagnosed during 1 January 2009 to 31 December 2018. We evaluated non-adherence to any ACE inhibitor, angiotensin receptor blocker, \u03b2-blocker or mineralocorticoid receptor antagonist, over 24 months. Non-adherence was based on proportion of days covered (PDC) and defined as PDC&lt;80%. Risk factors for non-adherence and all-cause mortality were examined using multiple logistic regression and Cox regression, respectively. Rates of any-cause emergency hospitalisations, cardiovascular disease (CVD) and HF mortality was estimated using Fine-Gray competing risk models. PDC was also assessed as a continuous variable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>About 43.6% of patients were non-adherent to therapy. Crude rates of emergency admissions, all-cause, CVD and HF mortality overall were 306.8\/1000, 119.6\/1000, 44.6\/1000 and 3.3\/1000 person-years, respectively. The strongest predictor of non-adherence was any-cause hospitalisation \u226412 months prior. Non-adherence was associated with a higher rate of all-cause mortality (HR 1.31, 95% CI 1.28 to 1.33) and significantly associated with CVD-related mortality (subdistribution HR (SHR) 1.20, 95% CI 1.16 to 1.23), HF deaths (SHR 1.18, 95% CI 1.05 to 1.32) and any-cause emergency admissions (SHR 1.11, 95% CI 1.10 to 1.13). In the analysis treating PDC as a continuous variable, every 10% decrease in PDC levels was associated with a 6% increased hazard of all-cause mortality (HR 1.06, 95% CI 1.05 to 1.06) and was significantly associated with CVD, but not HF mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Medication non-adherence over 24 months was relatively high and associated with poorer health outcomes. Interventions to improve adherence among patients with HF are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2025-003373","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:20:25Z","timestamp":1758691225000},"page":"e003373","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Non-adherence to medications prescribed to patients with heart failure in general practice: prevalence, risk factors and association with mortality and hospitalisation"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-0520","authenticated-orcid":false,"given":"Tarita","family":"Murray-Thomas","sequence":"first","affiliation":[{"name":"Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9978-2011","authenticated-orcid":false,"given":"Alex","family":"Bottle","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4665-6422","authenticated-orcid":false,"given":"Jamil","family":"Mayet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8976-890X","authenticated-orcid":false,"given":"Puja","family":"Myles","sequence":"additional","affiliation":[{"name":"Clinical Practice Research Datalink, Medicines and Healthcare products Regulatory Agency, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2026010701110242000_12.2.e003373.1","first-page":"81","article-title":"Understanding Hospitalization in Patients with Heart Failure","volume":"30","author":"Mesquita","year":"2016","journal-title":"International Journal of Cardiovascular Sciences"},{"key":"2026010701110242000_12.2.e003373.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.812172"},{"key":"2026010701110242000_12.2.e003373.3","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2021-320131"},{"key":"2026010701110242000_12.2.e003373.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"2026010701110242000_12.2.e003373.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.12.028"},{"key":"2026010701110242000_12.2.e003373.6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.12688\/f1000research.19365.1","article-title":"Humanistic burden and economic impact of heart failure \u2013 a systematic review of the literature","volume":"8","author":"Giles","year":"2019","journal-title":"F1000Res"},{"key":"2026010701110242000_12.2.e003373.7","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.876","article-title":"The global burden of heart failure: a systematic analysis for the Global Burden of Disease Study 2021","volume":"44","author":"Roth","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010701110242000_12.2.e003373.8","unstructured":"NHS Digital . Prevalence, achievement and personalised care adjustments region and national level. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data\/2021-22 [Accessed 20 Nov 2023]."},{"key":"2026010701110242000_12.2.e003373.9","unstructured":"NHS Digital . Prevalence quality and outcomes framework (QOF) for April 2009. 2010. Available: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/quality-and-outcomes-framework-achievement-prevalence-and-exceptions-data\/2021-22 [Accessed 20 Nov 2023]."},{"key":"2026010701110242000_12.2.e003373.10","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2333"},{"key":"2026010701110242000_12.2.e003373.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000435"},{"key":"2026010701110242000_12.2.e003373.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.04.011"},{"key":"2026010701110242000_12.2.e003373.13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/phar.2107","article-title":"Association Between Medication Adherence and the Outcomes of Heart Failure","volume":"38","author":"Hood","year":"2018","journal-title":"Pharmacotherapy"},{"key":"2026010701110242000_12.2.e003373.14","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/clc.23898","article-title":"Adherence with cardiovascular medications and the outcomes in patients with coronary arterial disease: \u201cReal-world\u201d evidence","volume":"45","author":"Chen","year":"2022","journal-title":"Clin Cardiol"},{"key":"2026010701110242000_12.2.e003373.15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67760-4"},{"key":"2026010701110242000_12.2.e003373.16","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)92095-Y"},{"key":"2026010701110242000_12.2.e003373.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086596","article-title":"SUrvey of Guideline Adherence for Treatment of Systolic Heart Failure in Real World (SUGAR): a multi-center, retrospective, observational study","volume":"9","author":"Yoo","year":"2014","journal-title":"PLoS One"},{"key":"2026010701110242000_12.2.e003373.18","doi-asserted-by":"publisher","DOI":"10.1002\/EJHF.1459"},{"key":"2026010701110242000_12.2.e003373.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.669101"},{"key":"2026010701110242000_12.2.e003373.20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ehf2.13079","article-title":"Adherence to beta-blockers and long-term risk of heart failure and mortality after a myocardial infarction","volume":"8","author":"Desta","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010701110242000_12.2.e003373.21","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2026010701110242000_12.2.e003373.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-018-0442-4"},{"key":"2026010701110242000_12.2.e003373.23","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-198808000-00007"},{"key":"2026010701110242000_12.2.e003373.24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1177\/1536867X19893625","article-title":"Assessing medication adherence using Stata","volume":"19","author":"Linden","year":"2019","journal-title":"The Stata Journal"},{"key":"2026010701110242000_12.2.e003373.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.017719"},{"key":"2026010701110242000_12.2.e003373.26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007998","article-title":"Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure","volume":"7","author":"Chang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026010701110242000_12.2.e003373.27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.18553\/jmcp.2014.20.10.1018","article-title":"Medication Adherence to Specific Drug Classes in Chronic Heart Failure","volume":"20","author":"Viana","year":"2014","journal-title":"JMCP"},{"key":"2026010701110242000_12.2.e003373.28","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.505636"},{"key":"2026010701110242000_12.2.e003373.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2011.00263.x"},{"key":"2026010701110242000_12.2.e003373.30","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-012-9321-3"},{"key":"2026010701110242000_12.2.e003373.31","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician\u2019s prescriptions to patient\u2019s dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010701110242000_12.2.e003373.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.12.017"},{"key":"2026010701110242000_12.2.e003373.33","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000163641.86870.af"},{"key":"2026010701110242000_12.2.e003373.34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0296527","article-title":"Comorbidities in heart failure patients that predict cardiovascular readmissions within 100 days-An observational study","volume":"19","author":"Scholten","year":"2024","journal-title":"PLoS One"},{"key":"2026010701110242000_12.2.e003373.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102164","article-title":"Prognosis, characteristics, and provision of care for patients with the unspecified heart failure electronic health record phenotype: a population-based linked cohort study of 95262 individuals","volume":"63","author":"Nakao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026010701110242000_12.2.e003373.36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx026"},{"key":"2026010701110242000_12.2.e003373.37","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002606","article-title":"Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta-Analysis of Controlled Trials","volume":"5","author":"Ruppar","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026010701110242000_12.2.e003373.38","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.19271"},{"key":"2026010701110242000_12.2.e003373.39","doi-asserted-by":"publisher","DOI":"10.1002\/hec.609"},{"key":"2026010701110242000_12.2.e003373.40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jval.2015.07.009","article-title":"The Reporting of Treatment Nonadherence and Its Associated Impact on Economic Evaluations Conducted Alongside Randomized Trials: A Systematic Review","volume":"19","author":"Brilleman","year":"2016","journal-title":"Value Health"},{"key":"2026010701110242000_12.2.e003373.41","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011711-113247"},{"key":"2026010701110242000_12.2.e003373.42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/bcp.14240","article-title":"How the EMERGE guideline on medication adherence can improve the quality of clinical trials","volume":"86","author":"Eliasson","year":"2020","journal-title":"Br J Clin Pharmacol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2025-003373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T09:11:22Z","timestamp":1767777082000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2025-003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,23]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/openhrt-2025-003373"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2025-003373","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}